These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. High serum concentrations of sialyl Tn antigen in carcinomas of the biliary tract and pancreas. Nanashima A; Yamaguchi H; Nakagoe T; Matsuo S; Sumida Y; Tsuji T; Sawai T; Yamaguchi E; Yasutake T; Ayabe H J Hepatobiliary Pancreat Surg; 1999; 6(4):391-5. PubMed ID: 10664288 [TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma. Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775 [TBL] [Abstract][Full Text] [Related]
27. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Haglund C; Lundin J; Kuusela P; Roberts PJ Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735 [TBL] [Abstract][Full Text] [Related]
28. Molecular forms of immunoreactive pancreatic cationic trypsin in pancreatitis patient sera. Brodrick JW; Geokas MC; Largman C; Fassett M; Johnson JH Am J Physiol; 1979 Nov; 237(5):E474-80. PubMed ID: 91323 [TBL] [Abstract][Full Text] [Related]
29. A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Sandanayake NS; Sinclair J; Andreola F; Chapman MH; Xue A; Webster GJ; Clarkson A; Gill A; Norton ID; Smith RC; Timms JF; Pereira SP Br J Cancer; 2011 Oct; 105(9):1370-8. PubMed ID: 21970875 [TBL] [Abstract][Full Text] [Related]
30. Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer. Kobayashi T; Kawa S; Tokoo M; Oguchi H; Kiyosawa K; Furuta S; Kanai M; Homma T Scand J Gastroenterol; 1991 Jul; 26(7):787-97. PubMed ID: 1896821 [TBL] [Abstract][Full Text] [Related]
31. Immunoreactive trypsins in sera from dogs before and after induction of experimental pancreatitis. Borgström A; Ohlsson K Hoppe Seylers Z Physiol Chem; 1980 May; 361(5):625-31. PubMed ID: 6159294 [TBL] [Abstract][Full Text] [Related]
32. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions. Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676 [TBL] [Abstract][Full Text] [Related]
33. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy. Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425 [TBL] [Abstract][Full Text] [Related]
34. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease. Zabron AA; Horneffer-van der Sluis VM; Wadsworth CA; Laird F; Gierula M; Thillainayagam AV; Vlavianos P; Westaby D; Taylor-Robinson SD; Edwards RJ; Khan SA Am J Gastroenterol; 2011 Sep; 106(9):1711-7. PubMed ID: 21670771 [TBL] [Abstract][Full Text] [Related]
35. PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer. Yi Q; Dong F; Lin L; Liu Q; Chen S; Gao F; He Q Tumour Biol; 2016 May; 37(5):5805-10. PubMed ID: 26546433 [TBL] [Abstract][Full Text] [Related]
36. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin. Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978 [TBL] [Abstract][Full Text] [Related]
37. Alpha-1-antitrypsin and lysozyme. Their limited significance in fibrohistiocytic tumors. Soini Y; Miettinen M Am J Clin Pathol; 1989 May; 91(5):515-21. PubMed ID: 2541606 [TBL] [Abstract][Full Text] [Related]
38. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice. Ng WW; Tong KJ; Tam TN; Lee SD Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181 [TBL] [Abstract][Full Text] [Related]
39. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Koopmann J; Thuluvath PJ; Zahurak ML; Kristiansen TZ; Pandey A; Schulick R; Argani P; Hidalgo M; Iacobelli S; Goggins M; Maitra A Cancer; 2004 Oct; 101(7):1609-15. PubMed ID: 15378479 [TBL] [Abstract][Full Text] [Related]
40. Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases. Ozkan H; Akar T; Köklü S; Coban S Pancreatology; 2006; 6(4):268-72. PubMed ID: 16636598 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]